Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment

Current Pharmaceutical Biotechnology

Volumn 12, Issue 2, 2011, Pages 196-205

  Nicolini, A ^a   Ferrari, P ^a   Fini, M ^b   Borsari, V ^b   Fallahi, P ^a   Antonelli, A ^a   Berti, P ^c   Carpi, A ^a   Miccoli, P ^c  

^a UNIVERSITY OF PISA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c Department of Surgery ^*  (Italy)

Author keywords

Breast cancer; Cancer stem cells; Chemotherapy; Hormonetherapy; Radiotherapy; Resistance

Indexed keywords

CD24 ANTIGEN; HERMES ANTIGEN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FATE; CELL RENEWAL; GENE MUTATION; HORMONAL THERAPY; HUMAN; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; TUMOR MICROENVIRONMENT; UPREGULATION;

MUS;

EID: 79551634949     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794295657     Document Type: Article

References (96)

1. Groner, B.; Vafaizadeh, V.; Brill, B.; Klemmt, P. Mammary epithelial and breast cancer stem cells. Eur. J. Cancer, 2009, 45(1),186-193.
2. Clarke, M. F.; Weissman, I. L. Abeloff, M. D.; Armitage, J. O.; Niederhuber, J. E.; Kastan M. B.; Gillies McKenna, W. Eds.; Stem cells, cell differentiation and cancer. In: Clinical Oncology; Chp. 7, Churchill Livingstone Elsevier: Philadelphia P.A., 2008, p. 95.
3. Smith, G.H.; Medina, D. A morphologically distinct candidate for an epithelial stem cell in mouse mammary gland. J. Cell. Sci., 1988, 90(1), 173-183.
4. Smith, G. H. Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res. Treat., 1996, 39(1), 21-31.
5. Villadsen, R.; Fridriksdottir, A. J.; Rønnov-Jessen, L.; Gudjonsson, T.; Rank, F.; LaBarge, M. A.; Bissell, M. J.; Petersen, O. W. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol., 2007, 177(1), 87-101.
6. Gudjonsson, T.; Villadsen, R.; Nielsen, H. L.; Rønnov-Jessen, L.; Bissell, M. J.; Petersen, O.W. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev., 2002, 16(6), 693-706.
7. Shackleton, M.; Vaillant, F.; Simpson, K. J.; Stingl, J.; Smyth, G. K.; Asselin-Labat, M. L.; Wu, L.; Lindeman, G. J.; Visvader, J. E., Generation of a functional mammary gland from a single stem cell. Nature, 2006, 439(7072), 84-88.
8. Ginestier, C.; Hur, M. H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C. G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007, 1(5),555-567.
9. Raouf, A.; Zhao, Y.; To, K.; Stingl, J.; Delaney, A.; Barbara, M.; Iscove, N.; Jones, S.; McKinney, S.; Emerman, J.; Aparicio, S.; Marra, M.; Eaves, C. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell, 2008, 3(1), 109-118.
10. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414(6859),105-111.
11. Al-Hajj, M.; Wicha, M. S.; Benito-Hernandez, A.; Morrison, S. J.; Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100(7), 3983-3988.
12. Al-Hajj, M.; Clarke, M. F. Self-renewal and solid tumor stem cells. Oncogene, 2004, 23(43), 7274-7282.
13. Dalerba, P.; Cho, R. W.; Clarke, M. F. Cancer stem cells: models and concepts. Annu. Rev. Med., 2007, 58, 267-284.
14. Lawson, J. C.; Blatch, G. L.; Edkins, A. L. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res. Treat., 2009, 118(2), 241-254.
15. Wicha, M. S.; Liu, S.; Dontu, G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res., 2006, 66(4), 1883-1890.
16. Hill, R. P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res., 2006, 66(4), 1891-1895.
17. Fillmore, C. M.; Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 2008, 10(2), R25.
18. Polyak, K. Is breast tumor progression really linear? Clin. Cancer Res., 2008, 14(2), 339-341.
19. Kondo, M.; Scherer, D. C.; Miyamoto, T.; King, A. G.; Akashi, K.; Sugamura, K.; Weissman, I. L. Cell-fate conversion of lymphoidcommitted progenitors by instructive actions of cytokines. Nature, 2000, 407(6802), 383-386.
20. Pollett, J. B.; Corsi, K. A.; Weiss, K. R.; Cooper, G. M.; Barry, D. A.; Gharaibeh, B.; Huard, J. Malignant transformation of multipotent muscle-derived cells by concurrent differentiation signals. Stem Cells, 2007, 25(9), 2302-2311.
21. Shipitsin, M.; Campbell, L. L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; Halushka, M. K.; Sukumar, S.; Parker, L. M.; Anderson, K. S.; Harris, L. N.; Garber, J. E.; Richardson, A. L.; Schnitt, S. J.; Nikolsky, Y.; Gelman, R. S.; Polyak, K. Molecular definition of breast tumor heterogeneity. Cancer Cell, 2007, 11(3), 259-273.
22. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Wicinski, J.; Cervera, N.; Finetti, P.; Hur, M. H.; Diebel, M. E.; Monville, F.; Dutcher, J.; Brown, M.; Viens, P.; Xerri, L.; Bertucci, F.; Stassi, G.; Dontu, G.; Birnbaum, D.; Wicha, M. S. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res., 2009, 69(4), 1302-1313.
23. Charafe-Jauffret, E.; Monville, F.; Ginestier, C.; Dontu, G.; Birnbaum, D.; Wicha, M. S. Cancer stem cells in breast: current opinion and future challenges. Pathobiology, 2008, 75(2),75-84.
24. Molyneux, G.; Regan, J.; Smalley, M. J. Mammary stem cells and breast cancer. Cell. Mol. Life Sci., 2007, 64(24), 3248-3260.
25. Polyak, K. Breast cancer: origins and evolution. J. Clin. Invest., 2007, 117(11), 3155-3163.
26. Burns, J. S.; Abdallah, B. M.; Guldberg, P.; Rygaard, J.; Schrøder, H. D.; Kassem, M. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res., 2005, 65(8), 3126-3135.
27. Røsland, G. V.; Svendsen, A.; Torsvik, A.; Sobala, E.; McCormack, E.; Immervoll, H.; Mysliwietz, J.; Tonn, J. C.; Goldbrunner, R.; Lønning, P.E.; Bjerkvig, R.; Schichor, C. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res., 2009, 69(13), 5331-5339.
28. Rubio, D.; Garcia-Castro, J.; Martín, M. C.; De la Fuente, R.; Cigudosa, J. C.; Lloyd, A. C.; Bernad, A. Spontaneous human adult stem cell transformation. Cancer Res., 2005, 65(8), 3035-3039.
29. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4), 663-676.
30. Honeth, G.; Bendahl, P. O.; Ringnér, M.; Saal, L. H.; Gruvberger-Saal, S. K.; Lövgren, K.; Grabau, D.; Fernö, M.; Borg, A; Hegardt, C. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res., 2008, 10(3), R53.
31. Sheridan, C.; Kishimoto, H.; Fuchs, R. K.; Mehrotra, S.; Bhat,-Nakshatri, P.; Turner, C. H.; Goulet, R. Jr.; Badve, S.; Nakshatri, H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res., 2006, 8(5), R59.
32. Vaillant, F.; Asselin-Labat, M. L.; Shackleton, M.; Forrest, N. C.; Lindeman, G. J.; Visvader, J. E. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res., 2008, 68(19), 7711-7717.
33. Korkaya, H.; Wicha, M. S. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin. Cancer Res., 2009, 15(6), 1845-1847.
34. Liu, S.; Dontu, G.; Wicha, M. S. Mammary stem cells, self-renewal pathways, andcarcinogenesis. Breast Cancer Res., 2005, 7(3), 86-95.
35. Li, Y.; Welm, B.; Podsypanina, K.; Huang, S.; Chamorro, M.; Zhang, X.; Rowlands, T.; Egeblad, M.; Cowin, P.; Werb, Z.; Tan, L. K.; Rosen, J. M.; Varmus, H. E. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. USA, 2003, 100(26), 15853-15858.
36. Korkaya, H.; Paulson, A.; Charafe-Jauffret, E.; Ginestier, C.; Brown, M.; Dutcher, J.; Clouthier, S. G.; Wicha, M. S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol., 2009, 7(6), e1000121.
37. Wang, Z.; Li, Y.; Banerjee, S.; Sarkar, F. H. Emerging role of Notch in stem cells and cancer. Cancer Lett., 2009, 279(1), 8-12.
38. Zardawi, S.J.; O'Toole, S. A.; Sutherland, R. L.; Musgrove, E. A. Dysregulation of hedgehog, wnt and notch signalling pathways in breast cancer. Histol. Histopathol., 2009, 24(3), 385-398.
39. Farnie, G.; Clarke, R. B. Mammary stem cells and breast cancerrole of Notch signalling. Stem Cell Rev., 2007, 3(2), 169-175.
40. Mine, T.; Matsueda, S.; Li, Y.; Tokumitsu, H.; Gao, H.; Danes, C.; Wong, K. K.; Wang, X.; Ferrone, S.; Ioannides, C. G. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol. Immunother., 2009, 58(8),1185-1194.
41. Liu, S.; Dontu, G.; Mantle, I. D.; Patel, S.; Ahn, N. S.; Jackson, K. W.; Suri, P.; Wicha, M. S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res., 2006, 66(12), 6063-6071.
42. Fillmore, C.; Kuperwasser, C. Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man? Breast Cancer Res., 2007, 9(3), 303.
43. Dontu, G. Breast cancer stem cell markers - the rocky road to clinical applications. Breast Cancer Res., 2008, 10(5), 110.
44. Quintana, E.; Shackleton, M.; Sabel, M. S.; Fullen, D. R.; Johnson, T. M.; Morrison, S. J. Efficient tumour formation by single human melanoma cells. Nature, 2008, 456(7222), 593-598.
45. Balic, M.; Lin, H.; Young, L.; Hawes, D.; Giuliano, A.; McNamara, G.; Datar, R.H.; Cote, R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res., 2006, 12(19), 5615-5621.
46. Abeloff, M. D.; Wolff, A. C.; Weber, B. L.; Zaks, T. Z.; Sacchini, V.; McCormick, B. Cancer of the breast. Abeloff, M. D.; Armitage, J. O.; Niederhuber, J. E.; Kastan, M. B., Gillies McKenna, W. Ed.; Clinical Oncology; Chp. 95, Churchill Livingstone Elsevier: Philadelphia PA, 2008; p. 1875.
47. Brown, L. F.; Berse, B.; Van de Water, L.; Papadopoulos-Sergiou, A.; Perruzzi, C. A.; Manseau, E. J.; Dvorak, H. F.; Senger, D. R. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol. Biol. Cell., 1992, 3(10), 1169-1180.
48. Draffin, J. E.; McFarlane, S.; Hill, A.; Johnston, P. G.; Waugh, D. J. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res., 2004, 64(16), 5702-5711.
49. Chakraborty, G.; Jain, S.; Kundu, G. C. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res., 2008, 68(1), 152-161.
50. Tuck, A. B.; Arsenault, D. M.; O'Malley, F. P.; Hota, C.; Ling, M. C.; Wilson, S. M.; Chambers A. F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 1999, 18(29), 4237-4246.
51. Kang, Y.; Siegel, P. M.; Shu, W.; Drobnjak, M.; Kakonen, S. M.; Cordón-Cardo, C.; Guise, T. A.; Massagué, J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3(6), 537-549.
52. Darash-Yahana, M.; Pikarsky, E.; Abramovitch, R.; Zeira, E.; Pal, B.; Karplus, R.; Beider, K.; Avniel, S.; Kasem, S.; Galun, E.; Peled, A. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J., 2004, 18(11), 1240-1242.
53. Schabath, H.; Runz, S.; Joumaa, S.; Altevogt, P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J. Cell Sci., 2006, 119(Pt 2), 314-325.
54. Kakarala, M.; Wicha, M. S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol., 2008, 26(17), 2813-2820.
55. Hay, E. D. An overview of epithelio-mesenchymal transformation. Acta Anat. (Basel) 1995, 154(1), 8-20.
56. Davies, J. A. Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Acta Anat. (Basel), 1996, 156(3), 187-201.
57. Hollier, B. G.; Evans, K.; Mani, S. A. The epithelial-tomesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia, 2009, 14(1), 29-43.
58. J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2002, 2(6), 442-454.
59. Yang, J.; Mani, S. A.; Donaher, J. L.; Ramaswamy, S.; Itzykson, R. A.; Come, C.; Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R. A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 2004, 117(7), 927-939.
60. Mani, S. A.; Yang, J.; Brooks, M.; Schwaninger, G.; Zhou, A.; Miura, N.; Kutok, J. L.; Hartwell, K.; Richardson, A. L.; Weinberg, R. A., Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc. Natl. Acad. Sci. USA, 2007, 104(24), 10069-10074.
61. Moustakas, A.; Heldin, C. H. m Signaling networks guiding epithelial- mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci., 2007, 98(10), 1512-1520.
62. Yangm J.; Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell, 2008, 14(6),818-829.
63. Peinado, H.; Olmeda, D.; Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 2007, 7(6),415-428.
64. Li, X.; Lewis, M. T.; Huang, J.; Gutierrez, C.; Osborne, C. K.; Wu, M. F.; Hilsenbeck, S. G.; Pavlick, A.; Zhang, X.; Chamness, G. C.; Wong, H.; Rosen, J.; Chang, J. C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst., 2008, 100(9), 672-679.
65. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 2007, 131(6), 1109-1123.
66. Jones, R.J.; Matsui, W.H., Smith, B.D. Cancer stem cells: are we missing the target? J. Natl. Cancer Inst., 2004, 96(8), 583-585.
67. Jordan, C. T.; Guzman, M. L.; Noble, M. Cancer stem cells. N. Engl. J. Med., 2006, 355(12), 1253-1261.
68. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
69. Chuthapisith, S.; Eremin, J.; El-Sheemey, M.; Eremin, O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg. Oncol., 2010, 19(1), 27-32.
70. Donnenberg, V. S.; Donnenberg, A. D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol., 2005, 45(8), 872-877.
71. Hirschmann-Jax, C.; Foster, A. E.; Wulf, G. G.; Nuchtern, J. G.; Jax, T. W.; Gobel, U.; Goodell, M. A.; Brenner, M. K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA, 2004, 101(39), 14228-14233.
72. Wang, S.; Yang, D.; Lippman, M. E. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin. Oncol., 2003, 30(5 Suppl 16), 133-142.
73. Sabbah, M.; Emami, S.; Redeuilh, G.; Julien, S.; Prévost, G.; Zimber, A.; Ouelaa, R.; Bracke, M.; De Wever, O.; Gespach, C. Molecular signature and therapeutic perspective of the epithelial-tomesenchymal transitions in epithelial cancers. Drug Resist. Updat, 2008, 11(4-5), 123-151.
74. Zhuo, W. L.; Wang, Y.; Zhuo, X.L.; Zhang, Y.S.; Chen, Z.T. Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem. Biophys. Res. Commun., 2008, 369(4), 1098-1102.
75. Kajiyama, H.; Shibata, K.; Terauchi, M.; Yamashita, M.; Ino, K.; Nawa, A.; Kikkawa, F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol., 2007, 31(2), 277-283.
76. Shah, A. N.; Summy, J. M.; Zhang, J.; Park, S. I.; Parikh, N. U.; Gallick, G. E. Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann. Surg. Oncol., 2007, 14(12), 3629-3637.
77. Cheng, G. Z.; Chan, J.; Wang, Q.; Zhang, W.; Sun, C.D.; Wang, L. H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res., 2007, 67(5), 1979-1987.
78. Kajita, M.; McClinic, K. N.; Wade, P. A. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol. Cell. Biol., 2004, 24(17), 7559-7566.
79. Dowsett, M.; Houghton, J.; Iden, C.; Salter, J.; Farndon, J.; A'Hern, R.; Sainsbury, R.; Baum, M. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol., 2006, 17(5), 818-826.
80. O'Brien, C. S.; Howell, S. J.; Farnie, G.; Clarke, R. B. Resistance to endocrine therapy: are breast cancer stem cells the culprits? J. Mammary Gland Biol. Neoplasia, 2009, 14 (1), 45-54.
81. Rizzo, P.; Miao, H.; D'Souza, G.; Osipo, C.; Song, L. L.; Yun, J.; Zhao, H.; Mascarenhas, J.; Wyatt, D.; Antico, G.; Hao, L.; Yao, K.; Rajan, P.; Hicks, C.; Siziopikou, K.; Selvaggi, S.; Bashir, A.; Bhandari, D.; Marchese, A.; Lendahl, U.; Qin, J. Z.; Tonetti, D. A; Albain, K.; Nickoloff, B. J.; Miele, L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res., 2008, 68(13), 5226-5235.
82. Horwitz, K. B., Dye, W. W., Harrell, J. C., Kabos, P., Sartorius, C. A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc. Natl. Acad. Sci., USA, 2008, 105(15), 5774-5779.
83. Hiscox, S.; Jordan, N.J.; Jiang, W.; Harper, M.; McClelland, R.; Smith, C.; Nicholson, R. I. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr. Relat. Cancer, 2006, 13(4), 1085-1099.
84. Hiscox, S.; Morgan, L.; Barrow, D.; Dutkowskil, C.; Wakeling, A.; Nicholson, R. I. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin. Exp. Metastasis, 2004, 21(3), 201-212.
85. Mine, S.; Fujisaki, T.; Kawahara, C.; Tabata, T.; Iida, T.; Yasuda, M.; Yoneda, T.; Tanaka, Y. Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. Exp. Cell. Res., 2003, 288(1), 189-197.
86. Harrell, J. C.; Dye, W.W.; Allred, D. C.; Jedlicka, P.; Spoelstra, N. S.; Sartorius, C. A.; Horwitz, K.B. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res., 2006, 66(18), 9308-9315.
87. Farmer, P.; Bonnefoi, H.; Anderle, P.; Cameron, D.; Wirapati, P.; Becette, V.; André, S.; Piccart, M.; Campone, M.; Brain, E.; Macgrogan, G.; Petit, T.; Jassem, J.; Bibeau, F.; Blot, E.; Bogaerts, J.; Aguet, M.; Bergh, J.; Iggo, R.; Delorenzi, M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med., 2009, 15(1), 68-74.
88. Bloushtain-Qimron, N.; Yao, J.; Snyder, E. L.; Shipitsin, M.; Campbell, L. L.; Mani, S. A.; Hu, M.; Chen, H.; Ustyansky, V.; Antosiewicz, J. E.; Argani, P.; Halushka, M. K.; Thomson, J. A.; Pharoah, P.; Porgador, A.; Sukumar, S.; Parsons, R.; Richardson, A. L.; Stampfer, M. R.; Gelman, R. S.; Nikolskaya, T.; Nikolsky, Y.; Polyak, K. Cell type-specific DNA methylation patterns in the human breast. Proc. Natl. Acad. Sci., USA, 2008, 105(37), 14076-14081.
89. Lower, E. E.; Glass, E. L.; Bradley, D. A.; Blau, R.; Heffelfinger, S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res. Treat., 2005, 90(1), 65-70.
90. Fehm, T.; Krawczyk, N.; Solomayer, E. F.; Becker-Pergola, G.; Dürr-Störzer, S.; Neubauer, H.; Seeger, H.; Staebler, A.; Wallwiener, D.; Becker, S. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res., 2008, 10(5), R76.
91. Lapidus, R. G.; Ferguson, A. T.; Ottaviano, Y. L.; Parl, F. F.; Smith, H. S.; Weitzman, S. A.; Baylin, S. B.; Issa, J. P.; Davidson, N. E. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res., 1996, 2(5), 805-810.
92. Badia, E.; Oliva, J.; Balaguer, P.; Cavaillès, V. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr., Med., Chem., 2007, 14(28), 3035-3045.
93. Phillips, T. M.; McBride, W. H.; Pajonk, F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst., 2006, 98(24), 1777-1785.
94. Bao, S.; Wu, Q.; McLendon, R. E.; Hao, Y.; Shi, Q.; Hjelmeland, A. B.; Dewhirst, M. W.; Bigner, D. D.; Rich, J. N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120), 756-760.
95. Woodward, W.A.; Chen, M. S.; Behbod, F.; Alfaro, M. P.; Buchholz, T. A.; Rosen, J. M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. USA, 2007, 104(2), 618-623.
96. Tsukamoto, H.; Shibata, K.; Kajiyama, H.; Terauchi, M.; Nawa, A.; Kikkawa, F. Irradiation-induced epithelial-mesenchymal transition (EMT) related to invasive potential in endometrial carcinoma cells. Gynecol. Oncol., 2007, 107(3), 500-504.